SKINConsumer Defensive · Household & Personal ProductsThe 9 Wall Street analysts covering Skinhealth Systems, Inc. hold a median 12-month price target of $1 — +51.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Skinhealth Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (13): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SKIN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +51.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | TD Cowen | Maintains | Hold | $1.00 → $0.90 |
| 20 May 2026 | Roth Capital | Reiterates | Buy | $2.50 → $2.00 |
| 20 May 2026 | Roth Capital | Reiterates | Buy | — |
| 1 May 2026 | Canaccord Genuity | Maintains | Hold | — |
| 16 Mar 2026 | TD Cowen | Maintains | Hold | — |
| 13 Mar 2026 | Canaccord Genuity | Maintains | Hold | — |
| 21 Jan 2026 | TD Cowen | Maintains | Hold | — |
| 14 Jan 2026 | Jefferies | Assumes | Hold | $1.60 |
| 22 Sept 2025 | TD Cowen | Maintains | Hold | — |
| 19 Sept 2025 | Roth Capital | Initiates | Buy | — |
| 1 Aug 2025 | Stifel | Maintains | Hold | — |
| 5 May 2025 | Canaccord Genuity | Maintains | Hold | — |
| 13 Mar 2025 | Canaccord Genuity | Maintains | Hold | — |
| 13 Nov 2024 | Canaccord Genuity | Maintains | Hold | — |
| 12 Aug 2024 | Canaccord Genuity | Maintains | Hold | — |
| 9 Aug 2024 | Piper Sandler | Reiterates | Underweight | — |
| 26 July 2024 | Stifel | Maintains | Hold | — |
| 11 July 2024 | Piper Sandler | Maintains | Underweight | — |
| 13 May 2024 | DA Davidson | Maintains | Buy | — |
| 13 May 2024 | TD Cowen | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SKIN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 90% of US stocks
Cheaper than 56% of US stocks
Cheaper than 31% of US stocks
Higher than 17% of US stocks
Higher than 27% of US stocks
Higher than 81% of US stocks
Higher than 55% of US stocks
Higher than 20% of US stocks
Higher than 23% of US stocks
Higher than 41% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Skinhealth Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research examines the evolution of SkinHealth Systems Inc.'s (SKIN) overseas revenue trends and how these international sales patterns affect Wall Street's forecasts and the stock's prospects.
Why it matters — A SKIN watcher would care because the company's international revenue performance can influence analyst forecasts and the stock's outlook.
Seeking Alpha published the transcript of SkinHealth Systems Inc.'s (SKIN) Q2 2026 earnings call. The transcript covers the company's earnings call for the quarter.
Why it matters — A SKIN watcher would care because the earnings call transcript provides direct information on the company's second-quarter performance and management commentary.
Beauty Health (NASDAQ: SKIN) reported second-quarter revenue at the low end of its guidance range, as cautious capital spending by providers weighed on equipment sales. Stronger gross margins and expense discipline lifted adjusted EBITDA above expectations.
Why it matters — A SKIN watcher would care because the quarter shows a contrast between soft equipment revenue due to cautious provider spending and better-than-expected profitability driven by improved margins and cost control.
Zacks Investment Research reports that SkinHealth Systems Inc. (SKIN) has released its Q2 2026 earnings, with the financial results compared against Wall Street estimates and year-ago figures. The article notes that aside from revenue and EPS, several key metrics warrant examination to gauge how the business performed in the quarter ended June 2026.
Why it matters — A SKIN watcher would care because the piece highlights how the company's key operating metrics stack up against analyst expectations and the prior-year period.
SkinHealth Systems Inc. (SKIN) reported a Q2 loss of $0.02 per share, which was narrower than the Zacks Consensus Estimate of a $0.04 loss but compared unfavorably with earnings of $0.03 per share a year earlier. Revenue also lagged estimates.
Why it matters — SKIN watchers would note the improved result versus analyst expectations, though the year-over-year swing from profit to loss signals weaker underlying performance.
The 9 Wall Street analysts covering Skinhealth Systems, Inc. have a median 12-month price target of $1, with estimates ranging from $0.85 to $1.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Skinhealth Systems, Inc., 1 rate it a Buy, 6 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Skinhealth Systems, Inc. 79 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Skinhealth Systems, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +51.2% from the last close, and Ticker Nerd's factor model ranks Skinhealth Systems, Inc. 79 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Skinhealth Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SKIN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.85 to $1.5 over the next 12 months.
Skinhealth Systems, Inc. returned -68.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
The Beauty Health Company designs, develops, manufactures, markets, and sells esthetic technologies and products focused on professional skin health treatments. Its flagship brand, Hydrafacial, delivers personalized facials that cleanse, extract, and hydrate the skin using proprietary serums and solutions through advanced delivery systems like Syndeo devices.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "SkinHealth Systems Inc. (SKIN) International Revenue Performance Explored". Zacks Investment Research examines the evolution of SkinHealth Systems Inc.'s (SKIN) overseas revenue trends and how these international sales patterns affect Wall Street's forecasts and the stock's prospects.
The Beauty Health Company designs, develops, manufactures, markets, and sells esthetic technologies and products focused on professional skin health treatments. Its flagship brand, Hydrafacial, delivers personalized facials that cleanse, extract, and hydrate the skin using proprietary serums and solutions through advanced delivery systems like Syndeo devices. Complementary offerings include SkinStylus, a microneedling and nanoneedling device for treating hypertrophic scars and acne scarring on specific skin types, and Keravive, featuring peptide solutions and take-home sprays for scalp health. The company also provides consumables such as single-use tips and boosters like Hydralock HA and HydraFillic with Pep9, enhancing treatment efficacy. Operating a skin health ecosystem, it supports providers via the MyBeautyHealth mobile app for consumer loyalty, personalized plans, and provider connections. Serving estheticians, dermatologists, and plastic surgeons across the Americas, Asia-Pacific, Europe, the Middle East, and Africa, The Beauty Health Company, founded in 1997 and headquartered in Long Beach, California, plays a key role in the professional aesthetics market by emphasizing recurring revenue from consumables and innovative, science-backed solutions.
CEO Ms. Marla Malcolm Beck · 769 employees · United States · https://www.beautyhealth.com